Phospholipid remodeling and its derivatives are associated with COVID-19 severity

[Display omitted] Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease’s pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging. We investigated the levels of...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 151; no. 5; pp. 1259 - 1268
Main Authors Wei, Juntong, Liu, Xiaoyu, Xiao, Weimin, Lu, Jiahua, Guan, Li, Fang, Zhangfu, Chen, Jiaping, Sun, Baoqing, Cai, Zongwei, Sun, Xizhuo, Chen, Hua-Ling, Zhong, Nanshan, Liu, Zhigang, Yang, Jun, Xiao, Xiaojun, Huang, Shau-Ku
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2023
Subjects
Online AccessGet full text
ISSN0091-6749
1097-6825
1097-6825
DOI10.1016/j.jaci.2022.11.032

Cover

Abstract [Display omitted] Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease’s pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging. We investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression. We performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease. Phospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models. Significant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19’s severity and pathogenesis.
AbstractList Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease's pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging. We investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression. We performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease. Phospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models. Significant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19's severity and pathogenesis.
Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease's pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging.BACKGROUNDTimely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease's pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging.We investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression.OBJECTIVEWe investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression.We performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease.METHODSWe performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease.Phospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models.RESULTSPhospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models.Significant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19's severity and pathogenesis.CONCLUSIONSignificant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19's severity and pathogenesis.
[Display omitted] Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease’s pathogenesis are essential for reducing mortality, but early classification of severe cases and its progression is challenging. We investigated the levels of circulating phospholipid metabolites and their relationship with COVID-19 severity, as well as the potential role of phospholipids in disease progression. We performed nontargeted lipidomic analysis of plasma samples (n = 150) collected from COVID-19 patients (n = 46) with 3 levels of disease severity, healthy individuals, and subjects with metabolic disease. Phospholipid metabolism was significantly altered in COVID-19 patients. Results of a panel of phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) and of phosphatidylethanolamine and lysophosphatidylethanolamine (LPE) ratios were significantly correlated with COVID-19 severity, in which 16 phospholipid ratios were shown to distinguish between patients with severe disease, mild disease, and healthy controls, 9 of which were at variance with those in subjects with metabolic disease. In particular, relatively lower ratios of circulating (PC16:1/22:6)/LPC 16:1 and (PE18:1/22:6)/LPE 18:1 were the most indicative of severe COVID-19. The elevation of levels of LPC 16:1 and LPE 18:1 contributed to the changes of related lipid ratios. An exploratory functional study of LPC 16:1 and LPE 18:1 demonstrated their ability in causing membrane perturbation, increased intracellular calcium, cytokines, and apoptosis in cellular models. Significant Lands cycle remodeling is present in patients with severe COVID-19, suggesting a potential utility of selective phospholipids with functional consequences in evaluating COVID-19’s severity and pathogenesis.
Author Liu, Xiaoyu
Fang, Zhangfu
Lu, Jiahua
Xiao, Weimin
Liu, Zhigang
Yang, Jun
Sun, Baoqing
Cai, Zongwei
Zhong, Nanshan
Chen, Hua-Ling
Wei, Juntong
Guan, Li
Xiao, Xiaojun
Huang, Shau-Ku
Sun, Xizhuo
Chen, Jiaping
Author_xml – sequence: 1
  givenname: Juntong
  orcidid: 0000-0002-6430-2038
  surname: Wei
  fullname: Wei, Juntong
  organization: Department of Respirology and Allergy. Third Affiliated Hospital of Shenzhen University. Shenzhen, China
– sequence: 2
  givenname: Xiaoyu
  surname: Liu
  fullname: Liu, Xiaoyu
  organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
– sequence: 3
  givenname: Weimin
  surname: Xiao
  fullname: Xiao, Weimin
  organization: Shenzhen Academy of Metrology and Quality Inspection, Shenzhen, China
– sequence: 4
  givenname: Jiahua
  surname: Lu
  fullname: Lu, Jiahua
  organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
– sequence: 5
  givenname: Li
  surname: Guan
  fullname: Guan, Li
  organization: Department of Respirology and Allergy. Third Affiliated Hospital of Shenzhen University. Shenzhen, China
– sequence: 6
  givenname: Zhangfu
  surname: Fang
  fullname: Fang, Zhangfu
  organization: Department of Respirology and Allergy. Third Affiliated Hospital of Shenzhen University. Shenzhen, China
– sequence: 7
  givenname: Jiaping
  surname: Chen
  fullname: Chen, Jiaping
  organization: Shenzhen Academy of Metrology and Quality Inspection, Shenzhen, China
– sequence: 8
  givenname: Baoqing
  surname: Sun
  fullname: Sun, Baoqing
  organization: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
– sequence: 9
  givenname: Zongwei
  surname: Cai
  fullname: Cai, Zongwei
  organization: State Key Laboratory of Environmental and Biological Analysis, Department of Chemistry, Hong Kong Baptist University, Hong Kong, China
– sequence: 10
  givenname: Xizhuo
  surname: Sun
  fullname: Sun, Xizhuo
  organization: Department of Respirology and Allergy. Third Affiliated Hospital of Shenzhen University. Shenzhen, China
– sequence: 11
  givenname: Hua-Ling
  surname: Chen
  fullname: Chen, Hua-Ling
  organization: National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli County, Taiwan
– sequence: 12
  givenname: Nanshan
  surname: Zhong
  fullname: Zhong, Nanshan
  organization: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
– sequence: 13
  givenname: Zhigang
  surname: Liu
  fullname: Liu, Zhigang
  organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
– sequence: 14
  givenname: Jun
  surname: Yang
  fullname: Yang, Jun
  email: 3244536@qq.com
  organization: Shenzhen Academy of Metrology and Quality Inspection, Shenzhen, China
– sequence: 15
  givenname: Xiaojun
  surname: Xiao
  fullname: Xiao, Xiaojun
  email: xiaojun1985918@126.com
  organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
– sequence: 16
  givenname: Shau-Ku
  surname: Huang
  fullname: Huang, Shau-Ku
  email: skhuang1@gmail.com
  organization: State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy and Immunology, Shenzhen University School of Medicine, Shenzhen, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36736798$$D View this record in MEDLINE/PubMed
BookMark eNqFkUFrFDEYQINU7Lb6BzxIjl5mzJfMZCbiRVZbC4UqFK8hk3zjZp2drEl2Zf-9Wba99FAhEELe-yAvF-RsDjMS8hZYDQzkh3W9NtbXnHFeA9RM8BdkAUx1lex5e0YWjCmoZNeoc3KR0pqVs-jVK3IuZFeW6hfkx_dVSNtVmPzWOxpxExxOfv5Fzeyoz4k6jH5vst9joiYiNSkF601GR__6vKLLu583XypQNOG-oPnwmrwczZTwzcN-Se6vvt4vv1W3d9c3y8-3lW1ayJUww9jIFpTkTY92ECjGBhGhUwOAFZwPIw6qbR02ghklJevLXVPkwbRMXJL3p7HbGP7sMGW98cniNJkZwy5p3nUCQAoJBX33gO6GDTq9jX5j4kE_VihAfwJsDClFHLX1ubw5zDkaP2lg-hhcr_UxuD4G1wC6BC8qf6I-Tn9W-nSSsPTZe4w6WY-zRecj2qxd8M_rH5_otnyZt2b6jYf_yf8AGbKr8A
CitedBy_id crossref_primary_10_1016_j_celrep_2024_114913
crossref_primary_10_3390_metabo13111107
crossref_primary_10_1016_j_phymed_2024_155968
crossref_primary_10_1093_procel_pwae006
crossref_primary_10_1007_s43440_023_00517_w
crossref_primary_10_1016_j_talanta_2023_125522
crossref_primary_10_3390_diseases12110285
crossref_primary_10_1002_ctm2_1440
crossref_primary_10_3389_fimmu_2024_1337208
crossref_primary_10_1111_cpr_13749
crossref_primary_10_1021_acs_jafc_3c05305
crossref_primary_10_17816_morph_628983
crossref_primary_10_1016_j_fochx_2023_100736
crossref_primary_10_3390_jcm12175478
crossref_primary_10_2147_JIR_S495227
crossref_primary_10_3390_ijms241713164
Cites_doi 10.1016/S0021-9258(18)70453-5
10.1073/pnas.1815356116
10.3389/fmicb.2019.00753
10.1016/j.cels.2020.10.003
10.1038/s41591-020-0819-2
10.1194/jlr.M500054-JLR200
10.1194/jlr.D700041-JLR200
10.1164/rccm.201306-1014OC
10.1016/j.cell.2020.05.032
10.1152/ajpendo.00198.2020
10.4049/jimmunol.178.10.6540
10.1016/j.jprot.2011.06.023
10.1183/13993003.01526-2020
10.1016/j.plipres.2011.06.001
10.1183/09031936.00209412
10.1038/nrd1776
10.1016/j.prostaglandins.2009.04.009
10.1189/jlb.0507292
10.1504/IJEX.2020.108602
10.1161/ATVBAHA.112.249854
10.1183/13993003.01740-2016
10.1093/nsr/nwaa086
10.3389/fmolb.2020.00012
10.18632/aging.103000
10.3390/cells9020473
10.1001/jama.2020.2648
10.1016/j.cmet.2020.06.016
10.1016/j.jhazmat.2019.121451
10.1016/j.cell.2020.10.037
10.1038/s41574-020-0353-9
10.1097/CCM.0000000000004411
10.1038/s41392-021-00508-4
ContentType Journal Article
Copyright 2023 American Academy of Allergy, Asthma & Immunology
Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2023 American Academy of Allergy, Asthma & Immunology
– notice: Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.jaci.2022.11.032
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-6825
EndPage 1268
ExternalDocumentID 36736798
10_1016_j_jaci_2022_11_032
S0091674923001422
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 22106108; U1801286; 31770984; 81901634
  funderid: https://doi.org/10.13039/501100001809
– fundername: Shenzhen Science and Technology
  grantid: KQTD20170331145453160
– fundername: Natural Science Foundation of Guangdong Province
  grantid: 2019A1515110407
  funderid: https://doi.org/10.13039/501100003453
– fundername: China Postdoctoral Science Foundation
  grantid: 2021M690785
  funderid: https://doi.org/10.13039/501100002858
– fundername: Key Science and Technology Project of
  grantid: JSGG20200225153031960
  funderid: https://doi.org/10.13039/100020450
GroupedDBID ---
--K
--M
-~X
.1-
.55
.FO
.GJ
.XZ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
354
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8F7
8FE
8FH
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAFWJ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADMUD
ADNMO
ADVLN
ADXHL
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AFFNX
AFJKZ
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
C45
CAG
CJTIS
COF
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDU
HMK
HMO
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
LK8
LUGTX
M27
M41
MO0
N4W
N9A
O-L
O9-
O9~
OAUVE
OBH
ODZKP
OHH
OHT
OK0
OK1
OVD
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SJN
SPCBC
SSH
SSI
SSZ
T5K
TEORI
TWZ
UGJ
UNMZH
UV1
WH7
WOW
WUQ
X7M
XFW
YOC
YQI
YQJ
Z5R
ZGI
ZXP
ZY1
~02
~G-
~KM
AACTN
RIG
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
EFLBG
ID FETCH-LOGICAL-c451t-3abf465196248ecb3e3f4eee179b11c322bfeb955de430a966081794451ba503
IEDL.DBID AIKHN
ISSN 0091-6749
1097-6825
IngestDate Thu Sep 04 17:57:23 EDT 2025
Thu Apr 03 07:07:27 EDT 2025
Tue Jul 01 04:21:57 EDT 2025
Thu Apr 24 23:12:52 EDT 2025
Sun Apr 06 06:53:01 EDT 2025
Tue Aug 26 16:37:31 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords LPE
PE O
LPC 16:1
PC O
APACHE II
phospholipid ratio
AUC
COVID-19
SARS-CoV-2
PC
FDR
PE
LPE 18:1
lipidomics
LPC
Language English
License Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c451t-3abf465196248ecb3e3f4eee179b11c322bfeb955de430a966081794451ba503
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-6430-2038
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/9891787
PMID 36736798
PQID 2773116361
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_2773116361
pubmed_primary_36736798
crossref_citationtrail_10_1016_j_jaci_2022_11_032
crossref_primary_10_1016_j_jaci_2022_11_032
elsevier_sciencedirect_doi_10_1016_j_jaci_2022_11_032
elsevier_clinicalkey_doi_10_1016_j_jaci_2022_11_032
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2023
2023-05-00
20230501
PublicationDateYYYYMMDD 2023-05-01
PublicationDate_xml – month: 05
  year: 2023
  text: May 2023
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of allergy and clinical immunology
PublicationTitleAlternate J Allergy Clin Immunol
PublicationYear 2023
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Wu, McGoogan (bib2) 2020; 323
Yu, Sun, Fang, Zhao, Liu, Li (bib3) 2020; 56
Cheng, Chien, Lai, Li, Lin, Ho (bib4) 2020; 9
Yilmaz, Ercan, Akduman, Ozilgen (bib5) 2020; 32
Su, Chen, Yuan, Lausted, Choi, Dai (bib14) 2020; 183
Kyle, Burnum-Johnson, Wendler, Eisfeld, Halfmann, Watanabe (bib6) 2019; 116
Shen, Yi, Sun, Bi, Du, Zhang (bib9) 2020; 182
Zou, Li, Fang, Hu, Bian, Ling (bib22) 2020; 48
Makide, Kitamura, Sato, Okutani, Aoki (bib25) 2009; 89
Wu, Shu, Yang, Song, Zhang, Yao (bib10) 2020; 7
Frisardi, Panza, Seripa, Farooqui, Farooqui (bib26) 2011; 50
Wang, Li, Lu, Huang (bib19) 2020; 12
Gauster, Rechberger, Sovic, Horl, Steyrer, Sattler (bib24) 2005; 46
Bornstein, Dalan, Hopkins, Mingrone, Boehm (bib20) 2020; 16
Ojala, Hirvonen, Hermansson, Somerharju, Parkkinen (bib32) 2007; 82
Wei, Li, Xiang, Song, Liu, Jiang (bib16) 2020; 390
Frasch, Zemski-Berry, Murphy, Borregaard, Henson, Bratton (bib28) 2007; 178
Matyash, Liebisch, Kurzchalia, Shevchenko, Schwudke (bib15) 2008; 49
Polonis, Wawrzyniak, Daghir-Wojtkowiak, Szyndler, Chrostowska, Melander (bib18) 2020; 7
Park, Lee, Berdyshev, Nyenhuis, Du, Fu (bib30) 2013; 188
Korakas, Ikonomidis, Kousathana, Balampanis, Kountouri, Raptis (bib21) 2020; 319
Lands (bib31) 1958; 231
Gonçalves, Edsfeldt, Young, Grufman, Berg, Björkbacka (bib23) 2012; 32
Larsson, Lundstrom, Pinto, Rankin, Karimpour, Blomberg (bib29) 2014; 43
Queiroz, Pinto, Lima, Giovanetti, de Jesus, Xavier (bib7) 2019; 10
Reinke, Gallart-Ayala, Gomez, Checa, Fauland, Naz (bib8) 2017; 49
Overmyer, Shishkova, Miller, Balnis, Bernstein, Peters-Clarke (bib12) 2021; 12
Li, Hou, Zhou, Wang, Tun, Zhu (bib11) 2021; 6
Song, Lam, Fan, Cao, Wang, Tian (bib13) 2020; 32
Del Boccio, Pieragostino, Di Ioia, Petrucci, Lugaresi, De Luca (bib27) 2011; 74
Thevarajan, Nguyen, Koutsakos, Druce, Caly, van de Sandt (bib1) 2020; 26
Wenk (bib17) 2005; 4
Wu (10.1016/j.jaci.2022.11.032_bib2) 2020; 323
Li (10.1016/j.jaci.2022.11.032_bib11) 2021; 6
Gonçalves (10.1016/j.jaci.2022.11.032_bib23) 2012; 32
Queiroz (10.1016/j.jaci.2022.11.032_bib7) 2019; 10
Song (10.1016/j.jaci.2022.11.032_bib13) 2020; 32
Wu (10.1016/j.jaci.2022.11.032_bib10) 2020; 7
Polonis (10.1016/j.jaci.2022.11.032_bib18) 2020; 7
Gauster (10.1016/j.jaci.2022.11.032_bib24) 2005; 46
Su (10.1016/j.jaci.2022.11.032_bib14) 2020; 183
Park (10.1016/j.jaci.2022.11.032_bib30) 2013; 188
Lands (10.1016/j.jaci.2022.11.032_bib31) 1958; 231
Cheng (10.1016/j.jaci.2022.11.032_bib4) 2020; 9
Wei (10.1016/j.jaci.2022.11.032_bib16) 2020; 390
Zou (10.1016/j.jaci.2022.11.032_bib22) 2020; 48
Del Boccio (10.1016/j.jaci.2022.11.032_bib27) 2011; 74
Shen (10.1016/j.jaci.2022.11.032_bib9) 2020; 182
Reinke (10.1016/j.jaci.2022.11.032_bib8) 2017; 49
Wenk (10.1016/j.jaci.2022.11.032_bib17) 2005; 4
Yilmaz (10.1016/j.jaci.2022.11.032_bib5) 2020; 32
Yu (10.1016/j.jaci.2022.11.032_bib3) 2020; 56
Larsson (10.1016/j.jaci.2022.11.032_bib29) 2014; 43
Ojala (10.1016/j.jaci.2022.11.032_bib32) 2007; 82
Korakas (10.1016/j.jaci.2022.11.032_bib21) 2020; 319
Matyash (10.1016/j.jaci.2022.11.032_bib15) 2008; 49
Frisardi (10.1016/j.jaci.2022.11.032_bib26) 2011; 50
Thevarajan (10.1016/j.jaci.2022.11.032_bib1) 2020; 26
Kyle (10.1016/j.jaci.2022.11.032_bib6) 2019; 116
Overmyer (10.1016/j.jaci.2022.11.032_bib12) 2021; 12
Makide (10.1016/j.jaci.2022.11.032_bib25) 2009; 89
Wang (10.1016/j.jaci.2022.11.032_bib19) 2020; 12
Bornstein (10.1016/j.jaci.2022.11.032_bib20) 2020; 16
Frasch (10.1016/j.jaci.2022.11.032_bib28) 2007; 178
References_xml – volume: 48
  start-page: E657
  year: 2020
  end-page: E665
  ident: bib22
  article-title: Acute Physiology and Chronic Health Evaluation II Score as a predictor of hospital mortality in patients of coronavirus disease 2019
  publication-title: Crit Care Med
– volume: 182
  start-page: 59
  year: 2020
  end-page: 72.e15
  ident: bib9
  article-title: Proteomic and metabolomic characterization of COVID-19 patient sera
  publication-title: Cell
– volume: 323
  start-page: 1239
  year: 2020
  end-page: 1242
  ident: bib2
  article-title: Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention
  publication-title: JAMA
– volume: 82
  start-page: 1501
  year: 2007
  end-page: 1509
  ident: bib32
  article-title: Acyl chain–dependent effect of lysophosphatidylcholine on human neutrophils
  publication-title: J Leukoc Biol
– volume: 9
  start-page: 473
  year: 2020
  ident: bib4
  article-title: Metabolic reprogramming of host cells in response to enteroviral infection
  publication-title: Cells
– volume: 50
  start-page: 313
  year: 2011
  end-page: 330
  ident: bib26
  article-title: Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer’s disease pathology
  publication-title: Prog Lipid Res
– volume: 89
  start-page: 135
  year: 2009
  end-page: 139
  ident: bib25
  article-title: Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol
  publication-title: Prostaglandins Other Lipid Mediat
– volume: 390
  year: 2020
  ident: bib16
  article-title: Metabolomics and lipidomics study unveils the impact of polybrominated diphenyl ether-47 on breast cancer mice
  publication-title: J Hazard Mater
– volume: 74
  start-page: 2826
  year: 2011
  end-page: 2836
  ident: bib27
  article-title: Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis
  publication-title: J Proteomics
– volume: 10
  start-page: 753
  year: 2019
  ident: bib7
  article-title: Lipidomic analysis reveals serum alteration of plasmalogens in patients infected with Zika virus
  publication-title: Front Microbiol
– volume: 49
  year: 2017
  ident: bib8
  article-title: Metabolomics analysis identifies different metabotypes of asthma severity
  publication-title: Eur Respir J
– volume: 26
  year: 2020
  ident: bib1
  article-title: Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
  publication-title: Nat Med
– volume: 116
  start-page: 3919
  year: 2019
  end-page: 3928
  ident: bib6
  article-title: Plasma lipidome reveals critical illness and recovery from human Ebola virus disease
  publication-title: Proc Natl Acad Sci U S A
– volume: 4
  start-page: 594
  year: 2005
  end-page: 610
  ident: bib17
  article-title: The emerging field of lipidomics
  publication-title: Nat Rev Drug Discov
– volume: 12
  start-page: 6049
  year: 2020
  end-page: 6057
  ident: bib19
  article-title: Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis
  publication-title: Aging (Albany NY)
– volume: 7
  start-page: 1157
  year: 2020
  end-page: 1168
  ident: bib10
  article-title: Plasma metabolomic and lipidomic alterations associated with COVID-19
  publication-title: Natl Sci Rev
– volume: 319
  start-page: E105
  year: 2020
  end-page: E109
  ident: bib21
  article-title: Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes
  publication-title: Am J Physiol Endocrinol Metab
– volume: 188
  start-page: 928
  year: 2013
  end-page: 940
  ident: bib30
  article-title: Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation
  publication-title: Am J Respir Crit Care Med
– volume: 16
  start-page: 297
  year: 2020
  end-page: 298
  ident: bib20
  article-title: Endocrine and metabolic link to coronavirus infection
  publication-title: Nat Rev Endocrinol
– volume: 56
  year: 2020
  ident: bib3
  article-title: Distinct features of SARS-CoV-2–specific IgA response in COVID-19 patients
  publication-title: Eur Respir J
– volume: 6
  start-page: 155
  year: 2021
  ident: bib11
  article-title: Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery
  publication-title: Signal Transduct Target Ther
– volume: 178
  start-page: 6540
  year: 2007
  end-page: 6548
  ident: bib28
  article-title: Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A
  publication-title: J Immunol
– volume: 32
  start-page: 1505
  year: 2012
  end-page: 1512
  ident: bib23
  article-title: Evidence supporting a key role of Lp-PLA2–generated lysophosphatidylcholine in human atherosclerotic plaque inflammation
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 49
  start-page: 1137
  year: 2008
  end-page: 1146
  ident: bib15
  article-title: Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics
  publication-title: J lipid Res
– volume: 46
  start-page: 1517
  year: 2005
  end-page: 1525
  ident: bib24
  article-title: Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine
  publication-title: J Lipid Res
– volume: 231
  start-page: 883
  year: 1958
  end-page: 888
  ident: bib31
  article-title: Metabolism of glycerolipides; a comparison of lecithin and triglyceride synthesis
  publication-title: J Biol Chem
– volume: 32
  start-page: 314
  year: 2020
  end-page: 327
  ident: bib5
  article-title: Energetic and exergetic costs of COVID-19 infection on the body of a patient
  publication-title: Int J Exergy
– volume: 12
  start-page: 23
  year: 2021
  ident: bib12
  article-title: Large-Scale multi-omic analysis of COVID-19 severity
  publication-title: Cell Syst
– volume: 32
  start-page: 188
  year: 2020
  ident: bib13
  article-title: Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis
  publication-title: Cell Metab
– volume: 183
  start-page: 1479
  year: 2020
  ident: bib14
  article-title: Multi-Omics resolves a sharp disease-state shift between mild and moderate COVID-19
  publication-title: Cell
– volume: 43
  start-page: 453
  year: 2014
  end-page: 463
  ident: bib29
  article-title: Lipid mediator profiles differ between lung compartments in asthmatic and healthy humans
  publication-title: Eur Respir J
– volume: 7
  start-page: 12
  year: 2020
  ident: bib18
  article-title: Metabolomic signature of early vascular aging (EVA) in hypertension
  publication-title: Front Mol Biosci
– volume: 231
  start-page: 883
  year: 1958
  ident: 10.1016/j.jaci.2022.11.032_bib31
  article-title: Metabolism of glycerolipides; a comparison of lecithin and triglyceride synthesis
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)70453-5
– volume: 116
  start-page: 3919
  year: 2019
  ident: 10.1016/j.jaci.2022.11.032_bib6
  article-title: Plasma lipidome reveals critical illness and recovery from human Ebola virus disease
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1815356116
– volume: 10
  start-page: 753
  year: 2019
  ident: 10.1016/j.jaci.2022.11.032_bib7
  article-title: Lipidomic analysis reveals serum alteration of plasmalogens in patients infected with Zika virus
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2019.00753
– volume: 12
  start-page: 23
  year: 2021
  ident: 10.1016/j.jaci.2022.11.032_bib12
  article-title: Large-Scale multi-omic analysis of COVID-19 severity
  publication-title: Cell Syst
  doi: 10.1016/j.cels.2020.10.003
– volume: 26
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib1
  article-title: Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
  publication-title: Nat Med
  doi: 10.1038/s41591-020-0819-2
– volume: 46
  start-page: 1517
  year: 2005
  ident: 10.1016/j.jaci.2022.11.032_bib24
  article-title: Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine
  publication-title: J Lipid Res
  doi: 10.1194/jlr.M500054-JLR200
– volume: 49
  start-page: 1137
  year: 2008
  ident: 10.1016/j.jaci.2022.11.032_bib15
  article-title: Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics
  publication-title: J lipid Res
  doi: 10.1194/jlr.D700041-JLR200
– volume: 188
  start-page: 928
  year: 2013
  ident: 10.1016/j.jaci.2022.11.032_bib30
  article-title: Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201306-1014OC
– volume: 182
  start-page: 59
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib9
  article-title: Proteomic and metabolomic characterization of COVID-19 patient sera
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.032
– volume: 319
  start-page: E105
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib21
  article-title: Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00198.2020
– volume: 178
  start-page: 6540
  year: 2007
  ident: 10.1016/j.jaci.2022.11.032_bib28
  article-title: Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A
  publication-title: J Immunol
  doi: 10.4049/jimmunol.178.10.6540
– volume: 74
  start-page: 2826
  year: 2011
  ident: 10.1016/j.jaci.2022.11.032_bib27
  article-title: Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis
  publication-title: J Proteomics
  doi: 10.1016/j.jprot.2011.06.023
– volume: 56
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib3
  article-title: Distinct features of SARS-CoV-2–specific IgA response in COVID-19 patients
  publication-title: Eur Respir J
  doi: 10.1183/13993003.01526-2020
– volume: 50
  start-page: 313
  year: 2011
  ident: 10.1016/j.jaci.2022.11.032_bib26
  article-title: Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer’s disease pathology
  publication-title: Prog Lipid Res
  doi: 10.1016/j.plipres.2011.06.001
– volume: 43
  start-page: 453
  year: 2014
  ident: 10.1016/j.jaci.2022.11.032_bib29
  article-title: Lipid mediator profiles differ between lung compartments in asthmatic and healthy humans
  publication-title: Eur Respir J
  doi: 10.1183/09031936.00209412
– volume: 4
  start-page: 594
  year: 2005
  ident: 10.1016/j.jaci.2022.11.032_bib17
  article-title: The emerging field of lipidomics
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd1776
– volume: 89
  start-page: 135
  year: 2009
  ident: 10.1016/j.jaci.2022.11.032_bib25
  article-title: Emerging lysophospholipid mediators, lysophosphatidylserine, lysophosphatidylthreonine, lysophosphatidylethanolamine and lysophosphatidylglycerol
  publication-title: Prostaglandins Other Lipid Mediat
  doi: 10.1016/j.prostaglandins.2009.04.009
– volume: 82
  start-page: 1501
  year: 2007
  ident: 10.1016/j.jaci.2022.11.032_bib32
  article-title: Acyl chain–dependent effect of lysophosphatidylcholine on human neutrophils
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.0507292
– volume: 32
  start-page: 314
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib5
  article-title: Energetic and exergetic costs of COVID-19 infection on the body of a patient
  publication-title: Int J Exergy
  doi: 10.1504/IJEX.2020.108602
– volume: 32
  start-page: 1505
  year: 2012
  ident: 10.1016/j.jaci.2022.11.032_bib23
  article-title: Evidence supporting a key role of Lp-PLA2–generated lysophosphatidylcholine in human atherosclerotic plaque inflammation
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.112.249854
– volume: 49
  year: 2017
  ident: 10.1016/j.jaci.2022.11.032_bib8
  article-title: Metabolomics analysis identifies different metabotypes of asthma severity
  publication-title: Eur Respir J
  doi: 10.1183/13993003.01740-2016
– volume: 7
  start-page: 1157
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib10
  article-title: Plasma metabolomic and lipidomic alterations associated with COVID-19
  publication-title: Natl Sci Rev
  doi: 10.1093/nsr/nwaa086
– volume: 7
  start-page: 12
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib18
  article-title: Metabolomic signature of early vascular aging (EVA) in hypertension
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2020.00012
– volume: 12
  start-page: 6049
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib19
  article-title: Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis
  publication-title: Aging (Albany NY)
  doi: 10.18632/aging.103000
– volume: 9
  start-page: 473
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib4
  article-title: Metabolic reprogramming of host cells in response to enteroviral infection
  publication-title: Cells
  doi: 10.3390/cells9020473
– volume: 323
  start-page: 1239
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib2
  article-title: Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention
  publication-title: JAMA
  doi: 10.1001/jama.2020.2648
– volume: 32
  start-page: 188
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib13
  article-title: Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2020.06.016
– volume: 390
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib16
  article-title: Metabolomics and lipidomics study unveils the impact of polybrominated diphenyl ether-47 on breast cancer mice
  publication-title: J Hazard Mater
  doi: 10.1016/j.jhazmat.2019.121451
– volume: 183
  start-page: 1479
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib14
  article-title: Multi-Omics resolves a sharp disease-state shift between mild and moderate COVID-19
  publication-title: Cell
  doi: 10.1016/j.cell.2020.10.037
– volume: 16
  start-page: 297
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib20
  article-title: Endocrine and metabolic link to coronavirus infection
  publication-title: Nat Rev Endocrinol
  doi: 10.1038/s41574-020-0353-9
– volume: 48
  start-page: E657
  year: 2020
  ident: 10.1016/j.jaci.2022.11.032_bib22
  article-title: Acute Physiology and Chronic Health Evaluation II Score as a predictor of hospital mortality in patients of coronavirus disease 2019
  publication-title: Crit Care Med
  doi: 10.1097/CCM.0000000000004411
– volume: 6
  start-page: 155
  year: 2021
  ident: 10.1016/j.jaci.2022.11.032_bib11
  article-title: Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-021-00508-4
SSID ssj0009389
Score 2.5027132
Snippet [Display omitted] Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease’s pathogenesis are...
Timely medical intervention in severe cases of coronavirus disease 2019 (COVID-19) and better understanding of the disease's pathogenesis are essential for...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1259
SubjectTerms COVID-19
Humans
lipidomics
LPC 16:1
LPE 18:1
Lysophosphatidylcholines - metabolism
phospholipid ratio
Phospholipids - metabolism
Title Phospholipid remodeling and its derivatives are associated with COVID-19 severity
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0091674923001422
https://dx.doi.org/10.1016/j.jaci.2022.11.032
https://www.ncbi.nlm.nih.gov/pubmed/36736798
https://www.proquest.com/docview/2773116361
Volume 151
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxsxEBapA6WX0nfdR1Cht6LEenp1DG6D05K0hbTkJvSYJRvK2thOjvntHe1qXXpICr0uO0jMaD59kuZByHuDlMN7OWUqmAlTPibmda1YbUVIOkJlunvIk1Mz_6E-n-vzHTIbcmFyWGXB_h7TO7QuXw6KNg-WTZNzfG0OoUeGknm-QBzeFdIaPSK7h8df5qd_au_KqmfBlrMsUHJn-jCvSx8bPCYKsZ-LeUpx2_50G__s9qGjR-RhIZD0sJ_jY7ID7RNy_6Q8kT8l379dLNZLxLRm2SS6gq7VDe5P1LeJNps1Tbjmrrty32vqV0B9MRAkmi9l6ezrz-OPjFuKc4Lc2u4ZOTv6dDabs9I3gUWl-YZJH-rc4twaoSqIQYKsFQCg7wXOI7pwqCFYrRMoOfG5PmeV_RKFg9cT-ZyM2kULLwk1VfQgvDGqQuaCh4lkfcovjxOAKiYYEz4oy8VSUzy3tvjlhuCxS5cV7LKC8bDhUMFj8mErs-wratz5txxs4IZcUUQ3h4B_p5TeSv21mv4p924ws0M3y28nvoXF1dqJ6VRy5K6Gj8mL3v7b2cscGze11av_HPU1eZCb2PdhlG_IaLO6grdIdTZhj9zbv-F7ZUH_BmMD-sQ
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELaqIgEX1PIM5WEkbshtdv3Y9RGFVik0BaSAerP8mFW3QpsoSTny25nZRxCHFonryqO1Zjzjz_Y3M4y9NQg5vJeFUMGMhfIxCa8rJSqbh6QjlKa9h5ydm-k39fFCX-ywyZALQ7TKPvZ3Mb2N1v2Xo16bR8u6phxfSxR6RCiE83OMw3eUlgXx-g5__eF5WFl2GNhmgob3mTMdyevKxxoPiXl-SKU8ZX7T7nQT-mx3oZM99qCHj_x9N8N9tgPNQ3Z31j-QP2Jfv1wu1kuMaPWyTnwFbaMb3J24bxKvN2uecMX9bIt9r7lfAfe9eSBxupLlk8_fTz-IzHKcE1Bju8dsfnI8n0xF3zVBRKWzjZA-VNTg3JpclRCDBFkpAEDPC1kW0YFDBcFqnUDJsafqnCV5JQoHr8fyCdttFg08Y9yU0UPujVEl4hY8SiTrE707jgHKmGDEskFZLvYVxamxxQ83UMeuHCnYkYLxqOFQwSP2biuz7Opp3DpaDjZwQ6YoxjaH4f5WKb2V-mst_VPuzWBmh05GLye-gcX12uVFITNEriYbsaed_bezl8SMK2z5_D__-prdm85nZ-7s9PzTAbtP7ew7QuULtrtZXcNLBD2b8Kpd1L8BfcH7jw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phospholipid+remodeling+and+its+derivatives+are+associated+with+COVID-19+severity&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=Wei%2C+Juntong&rft.au=Liu%2C+Xiaoyu&rft.au=Xiao%2C+Weimin&rft.au=Lu%2C+Jiahua&rft.date=2023-05-01&rft.issn=1097-6825&rft.eissn=1097-6825&rft.volume=151&rft.issue=5&rft.spage=1259&rft_id=info:doi/10.1016%2Fj.jaci.2022.11.032&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-6749&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-6749&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-6749&client=summon